Romiplostim for low platelets after chemotherapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had very low platelet counts (below 30) for more than a month, even after trying standard treatments like rhTPO or IL-11 for at least 14 days.
- You have stopped chemotherapy and radiation therapy for at least one month.
- Your doctor expects you to live at least 6 more months, and your liver, kidney, and heart function are relatively good.
- You do not have active serious bleeding, blood clots, uncontrolled infections, or certain heart conditions, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
This trial tests a new form of romiplostim (a drug that boosts platelets) in breast cancer patients whose platelet counts have dropped due to chemotherapy. It aims to see if it can safely raise platelet levels to reduce bleeding risk and allow chemo to continue.
This trial tests the safety and effectiveness of a drug called romiplostim for children ages 1 to 18 who have chronic ITP (a condition where the immune system destroys platelets, causing low platelet counts and bleeding risk). It may be an option for children whose ITP has not improved with or who cannot tolerate other treatments like steroids, IVIG, or eltrombopag.
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.